Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • In response to a written question in Rajya Sabha, Minister of State for Health Faggan Singh Kulaste stated that a subcommittee formed to consider issues related to online drug sales presented its recommendations suggesting the creation of a national portal to monitor such sales as well as certain restrictions imposed on them.

  • Antibiotic resistance is the result of environmental and behavioral causes. Indiscriminate antibiotic prescribing and lax enforcement laws are the main causes of antimicrobial resistance. This may be due to reckless use of antibiotics in hospitals as well as in private practice outside the easy availability of prescription drugs in the country.

  • Cytokinetics, Inc announced that it is scheduled to report fourth quarter results on Thursday, February 16, 2017 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.

  • Portola Pharmaceuticals, Inc.announced that it has signed a $150 million royalty agreement with HealthCare Royalty Partners (HCR). Under the terms of the agreement, Portola received $50 million at closing and may receive an additional $100 million upon U.S. Food and Drug Administration (FDA) approval of AndexXaTM (andexanet alfa) in exchange for a tiered, mid-single-digit royalty based on worldwide sales of the agent. The agreement is subject to a maximum total royalty payment of 195 percent of the $150 million funded by HCR, at which time the agreement would expire.

    [adsense:336x280:8701650588]

  • According to information provided by the Medical Council of India, there are a total of 9,88,922 allopathic doctors registered with the state medical council or MCI as of June 30, 2016.

  • Ferring Pharmaceuticals and Enteris BioPharma, Inc. announced that the companies have entered into a license agreement and initiated an early development agreement to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence™, to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring.

Subscribe to Pharma News